1. Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management

   • David S. Perlin

   Leading Article 26 September 2014 Pages: 1573 - 1585

   

2. Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications

   • Toby Trujillo
   • Paul P. Dobesh

   Review Article Open access 02 September 2014 Pages: 1587 - 1603

   

3. New Directions for Rabbit Antithymocyte Globulin (Thymoglobulin^®) in Solid Organ Transplants, Stem Cell Transplants and Autoimmunity

   • Mohamad Mohty
   • Andrea Bacigalupo
   • Yvon Lebranchu

   Review Article Open access 28 August 2014 Pages: 1605 - 1634

   

4. Turning a Molecule into a Medicine: the Development of Indacaterol as a Novel Once-Daily Bronchodilator Treatment for Patients with COPD

   • Lorraine Murphy
   • Stephen Rennard
   • David Young

   Review Article 12 September 2014 Pages: 1635 - 1657

   

5. OnabotulinumtoxinA (Botox^®): A Review of its Use in the Treatment of Urinary Incontinence in Patients with Multiple Sclerosis or Subcervical Spinal Cord Injury

   • Mark Sanford

   Adis Drug Evaluation 25 July 2014 Pages: 1659 - 1672

   

6. Lanreotide Autogel^®: A Review of its Use in the Treatment of Patients with Acromegaly

   • Celeste B. Burness
   • Sohita Dhillon
   • Susan J. Keam

   Adis Drug Evaluation 06 September 2014 Pages: 1673 - 1691

   

7. Omalizumab: A Review of Its Use in Patients with Chronic Spontaneous Urticaria

   • Paul L. McCormack

   Adis Drug Evaluation 13 September 2014 Pages: 1693 - 1699

   

8. Idelalisib: First Global Approval

   • Anthony Markham

   R&D Insight Report 04 September 2014 Pages: 1701 - 1707

9. Ataluren: First Global Approval

   • Nicola J. Ryan

   R&D Insight Report 06 September 2014 Pages: 1709 - 1714

   

10. Comment on “Treat-to-Target in Spondyloarthritis: Implications for Clinical Trial Designs”

    • Daniel Wendling
    • Clément Prati

    Letter to the Editor 16 September 2014 Pages: 1715 - 1716

11. Author's Reply to Wendling and Prati: “Treat-to-Target in Spondyloarthritis: Implications for Clinical Trial Designs”

    • James Cheng-Chung Wei

    Letter to the Editor 16 September 2014 Pages: 1717 - 1718